Save the date: InDex Pharmaceuticals to host Capital Markets Day in Stockholm on April 25, 2018

The purpose of the Capital Markets Day is to provide an overview of ulcerative colitis and the drug candidate cobitolimod from a scientific and market perspective. Cobitolimod is a first-in-class Toll-like receptor 9 (TLR9) agonist under development by InDex as a novel therapy for moderate to severe ulcerative colitis. Cobitolimod is currently being evaluated in the phase II study CONDUCT and the objective is to have top line results from the study in the fourth quarter of 2018.  

Members of InDex’s senior management will be joined by Professor Raja Atreya from the University of Erlangen-Nürnberg and Professor Walter Reinisch from the Medical University of Vienna, who are international Key Opinion Leaders within inflammatory bowel disease. They will share their expert clinical insights and their view on cobitolimod.

The day will start with registration at 9:00am CET and end with lunch and mingle at 12:00pm CET. The event will take place in Redeye’s premises on Mäster Samuelsgatan 42 in Stockholm.

The event will be in English and will be webcasted. A replay will be available on InDex webpage after the event. Further details will follow shortly.

If you wish to register already now, please send an email to [email protected].

For more information:
Peter Zerhouni, CEO
Phone: +46 8 508 847 35
E-mail: [email protected]

Cobitolimod in brief
Cobitolimod is a new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life. It is a so-called Toll-like receptor 9 (TLR9) agonist, that can provide an anti‐inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in active ulcerative colitis. Cobitolimod has achieved clinical proof-of-concept in moderate to severe active ulcerative colitis, with a very favorable safety profile. Data from four placebo-controlled clinical trials indicate that cobitolimod has statistically significant effects on those endpoints that are most relevant in this disease, both from a regulatory and clinical perspective. These endpoints include the key clinical symptoms such as blood in stool, number of stools, and mucosal healing, respectively.

Based on the encouraging results from earlier studies, InDex is now performing the phase IIb study CONDUCT to evaluate higher doses and dose frequencies than investigated in previous studies with cobitolimod. The goal of the study is to optimise the treatment and achieve substantially higher efficacy, while maintaining the compound’s excellent safety profile. The CONDUCT study will include 215 patients with left-sided moderate to severe active ulcerative colitis at 90 sites in 12 countries. It is a randomised, double blind, placebo-controlled study for evaluating cobitolimod’s efficacy and safety in inducing clinical remission compared to placebo. The dose optimisation study investigates three different dose strengths of cobitolimod and two different dose frequencies. The objective is to have top line results from the study in the fourth quarter of 2018. Cobitolimod is also known as Kappaproct® and DIMS0150. 

InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com